Suppr超能文献

PROMIS疲劳量表(MS)8a与传统疲劳问卷测量属性的比较。

A comparison of the measurement properties of the PROMIS Fatigue (MS) 8a against legacy fatigue questionnaires.

作者信息

Kamudoni Paul, Johns Jeffrey, Cook Karon F, Salem Rana, Salek Sam, Raab Jana, Middleton Rod, Henke Christian, Amtmann Dagmar

机构信息

Global Evidence & Value Development - R&D, Merck Healthcare KGaA, Darmstadt, Germany.

Institute of Medicines Development, Cardiff, UK.

出版信息

Mult Scler Relat Disord. 2022 Oct;66:104048. doi: 10.1016/j.msard.2022.104048. Epub 2022 Jul 9.

Abstract

BACKGROUND

Amidst the growing number of patient-reported outcome (PRO) measures of fatigue being used in multiple sclerosis (MS) clinical trials and clinics, evidence-based consensus on the most appropriate and generalizable measures across different settings would be beneficial for clinical research and patient care. The objective of this research was to compare the validity and responsiveness of scores from the PROMIS Fatigue (MS) 8a with those of the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS), across US and UK MS populations.

METHODS

Two observational studies were performed in MS populations as part of a PRO measure development project, including a cross-sectional study in two tertiary US MS centers (n = 340) and a 96-week longitudinal study in the UK MS Register cohort (n = 352). In post-hoc analyses, we examined  relative validity, based on ability to discriminate across patient groups with different fatigue levels or functional status at baseline (i.e., ANOVA-F PRO ÷ ANOVA-F PROMIS (MS) 8a), and relative responsiveness, based on baseline-to-Week-52 score change (effect sizes) across fatigue or functional status response groups .

RESULTS

Mean ± standard deviation (SD) age was 44.6 ± 11.3/50.0 ± 9.7; and 72.9%/77.3% were female (US/UK samples). The mean PROMIS Fatigue (MS) 8a T-score ± SD at baseline was 57.7 ± 10.5/58.9 ± 9.3 (US/UK samples). Compared with the PROMIS Fatigue (MS) 8a, relative validity (anchor: Global Health Score [GHS] fatigue global question) was 85% for MFIS symptom score, 48% for MFIS total score, and 44% for the FSS. Relative to the FSS, PROMIS Fatigue (MS) 8a scores were more sensitive to worsening (effect size = -0.43 versus -0.18) as well as improvement (effect size = 0.5 versus 0.2) in fatigue (≥1-point increase/decrease in GHS fatigue global question) over 52 weeks of follow-up. A similar pattern of score changes was observed based on a second anchor.

CONCLUSION

The PROMIS Fatigue (MS) 8a scores showed higher responsiveness to fatigue changes than those of the FSS. The PROMIS measure also had higher precision in differentiating levels of fatigue compared to the FSS, the MFIS physical, and MFIS total scores. These differences have practical implications for the application of these questionnaires in both clinical practice and research settings (e.g., sample size estimation in clinical trials).

摘要

背景

在多发性硬化症(MS)临床试验和诊所中,患者报告结局(PRO)疲劳测量方法的使用数量不断增加,就不同环境下最合适且可推广的测量方法达成基于证据的共识,将有利于临床研究和患者护理。本研究的目的是比较美国和英国MS人群中,患者报告结局测量信息系统(PROMIS)疲劳量表(MS)8a与疲劳严重程度量表(FSS)和改良疲劳影响量表(MFIS)得分的有效性和反应性。

方法

作为一项PRO测量方法开发项目的一部分,对MS人群进行了两项观察性研究,包括在美国两个三级MS中心进行的横断面研究(n = 340)和在英国MS注册队列中进行的为期96周的纵向研究(n = 352)。在事后分析中,我们基于区分基线时具有不同疲劳水平或功能状态的患者组的能力(即方差分析-F PRO÷方差分析-F PROMIS(MS)8a),检验了相对有效性;并基于疲劳或功能状态反应组中从基线到第52周得分的变化(效应量),检验了相对反应性。

结果

平均年龄±标准差(SD)为44.6±11.3/50.0±9.7;女性比例分别为72.9%/77.3%(美国/英国样本)。基线时,PROMIS疲劳量表(MS)8a的平均T得分±SD为57.7±10.5/58.9±9.3(美国/英国样本)。与PROMIS疲劳量表(MS)8a相比,MFIS症状得分的相对有效性(锚定:总体健康评分[GHS]疲劳总体问题)为85%,MFIS总分的相对有效性为48%,FSS的相对有效性为44%。相对于FSS,在52周的随访中,PROMIS疲劳量表(MS)8a得分对疲劳加重(效应量=-0.43对-0.18)以及改善(效应量=0.5对0.2)(GHS疲劳总体问题增加/减少≥1分)更为敏感。基于第二个锚定观察到了类似的得分变化模式。

结论

PROMIS疲劳量表(MS)8a得分对疲劳变化的反应性高于FSS。与FSS、MFIS身体维度得分和MFIS总分相比,PROMIS测量方法在区分疲劳水平方面也具有更高的精度。这些差异对于这些问卷在临床实践和研究环境中的应用具有实际意义(例如,临床试验中的样本量估计)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验